DOCSLIB.ORG

This Report 'Creating Clarity in a Time of Uncertainty'

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
This Report 'Creating Clarity in a Time of Uncertainty' Creating clarity in a time of uncertainty The Nuffield DepartmentEnter of Population Health’s contribution to the COVID-19 response 2020 → “The University of Oxford has responded swiftly and effectively to the COVID-19 pandemic, with colleagues across the Medical Sciences Division delivering major breakthroughs in the research response. NDPH focuses on providing reliable evidence on the causes, treatment and prevention of diseases that affect millions of people across the world. It has drawn on its multi-disciplinary expertise and the strengths of partners within and beyond the University to answer some of the most important research questions and respond at speed to a challenge unlike any other we have experienced.” Professor Sir John Bell, Regius Professor of Medicine, University of Oxford The Nuffield Department of underlying infrastructure, and → Our perinatal team is improving Population Health (NDPH) is uniquely longstanding partnerships to the care and treatment of babies placed to make a major contribution respond to the pandemic. and pregnant women directly and to the response to COVID-19 because indirectly affected by COVID-19. For example, our two registered it covers all aspects of population clinical trials units have longstanding → The Wolfson Laboratory team health and works at scale to provide experience in developing bespoke established the laboratory clarity about the most important research systems and delivering process for the biggest of the questions affecting human health. innovative, streamlined clinical Lighthouse laboratories. Introduction The department delivers randomised trials; we combined this experience → Our ethics expertise made trials, observational studies, ethics, with expertise in emerging viral a critical contribution to the Professor health economics and health infections in the Nuffield Department development and introduction services research, and is supported of Medicine (NDM) to deliver of mobile phone applications. Sir Rory Collins by dedicated laboratory, IT, the first major breakthrough Head of Department communications and administrative in the COVID-19 response. → We are shining a light on the wider staff. NDPH is a key partner in the impacts of COVID-19 for patients The department is working with Big Data Institute (BDI), a cross- with other diseases, such as heart partners in the UK and across department initiative that focuses disease and bowel cancer. the world to help solve the on the analysis of large, complex, problems that are having the This report provides an overview of heterogeneous data sets. greatest impact. For example: the work we have undertaken in 2020 We have built on our track record to support the COVID-19 effort. → In 2020, the RECOVERY trial of success in large-scale and delivered results on four potential global work and capitalised on COVID-19 treatments, changing our multi-disciplinary approach, clinical practice globally. The important questions and our contribution What are the How can What are How can we risk factors diagnostic testing the levels of design effective and effective be delivered infection and containment treatments? effectively? immunity? strategies? What are the How is COVID-19 How can longer term impacting wider we inform effects of SARS- public health and decision-making? CoV-2 infection? services? Testing treatments in the biggest in 2020 randomised trial of COVID-19 therapies 176 3 At the start of the COVID-19 pandemic, hospitals major results in 100 days nobody knew which treatments would be effective. The RECOVERY trial is a large, randomised controlled trial of possible treatments for patients admitted to hospital with COVID-19. 23340 9 participants days to set up The trial is focusing on testing treatments that are already used for other conditions. The trial is led by Professor Peter Horby in NDM 828000 website visitors 15203 items of media coverage which has world-leading expertise in infectious diseases, and by Professor Martin Landray in NDPH which has Diagnostic testing Surveillance Infection control Longer-term effects Wider impacts Public debate pioneered novel approaches to in global practice three times. treatments can be tested through delivering effective and streamlined It showed that two drugs used RECOVERY+, including treatments randomised clinical trials. to treat hospitalised COVID-19 tested in Phase II (smaller) and Phase patients throughout the world, III studies. The team are now preparing Over 23,000 patients were hydroxychloroquine and lopinavir- to deliver RECOVERY internationally, randomised to nine treatment arms, ritonavir, do not improve survival, with new sites being set up in or no additional treatment, in 176 “The UK has done really whilst one drug that was not Indonesia and Nepal. hospital sites across the UK between recommended, dexamethasone, saves March-December 2020. well on the therapeutics The trial is the best performing trial lives. The use of dexamethasone side… largely because anywhere for COVID-19 and is being The trial was set up at unprecedented following the RECOVERY trial of the huge success held up as the way forward for drug speed; it took just nine days from results is estimated to have saved trials. Academics from across the conception to launch. Over 10,000 of the Phase III trials approximately 12,000 lives in the UK world are drawing lessons from the patients were recruited in just two and particularly the and many more worldwide. pioneering design of the trial which months, making it the fastest ever RECOVERY study.” RECOVERY also found that there is minimises the impact on frontline teams recruiting individually randomised no benefit from use of the antibiotic, by integrating the research with clinical controlled trial. The trial is deliberately Sir Patrick Vallance, azithromycin, in patients hospitalised care and making best use of national inclusive: the youngest participant was UK Government Chief with COVID-19. The trial is continuing data sources. less than six months old and the oldest Scientific Adviser to test other treatments, including over 100 years, one-third are women, The trial is also generating wider Regeneron’s antibody cocktail. and one-sixth are of Black, Asian or understanding of the importance Minority Ethnic (BAME) background. Given the success of the Phase III of clinical trials in providing reliable RECOVERY trial, the UK Government evidence, and has been described as a In 100 days, the RECOVERY trial has increased investment so that new ‘beacon of excellence’. provided results enabling change Diagnostic testing Surveillance Infection control Longer-term effects Wider impacts Public debate This innovative approach paved (WHO). Both trials minimised the impact Streamlining the way for other successful trials on frontline staff by using simple online clinical trials designed and delivered by NDPH and enrolment, randomisation and follow- directly informed the design of the up forms, and embedding the research to provide RECOVERY trial and of SOLIDARITY, the in clinical practice. international COVID-19 treatment trial reliable evidence The SOLIDARITY protocol developed led by the World Health Organization “More than a third of trials rapidly by Professor Sir Richard Peto, enabled over 400 hospitals in have been too small to Professor Sir Richard Peto (NDPH) and over 30 countries to randomise provide conclusive answers. Professor Sir Rory Collins pioneered over 11,000 patients (from March- You have to do things at the concept of large simple trials for October 2020) to quickly and scale as RECOVERY and the International Studies of Infarct reliably answer critical questions. SOLIDARITY have done.” Survival (ISIS), a series of randomised The RECOVERY and SOLIDARITY “The SOLIDARITY trial Sir Jeremy Farrar, trials that assessed the effects of trials have demonstrated that provides simplified widely usable treatments on survival hydroxychloroquine, lopinavir (with Director of Wellcome following a heart attack. Around procedures to enable or without) ritonavir, azithromycin, 140,000 patients participated even hospitals that have interferon beta-1a and remdesivir Drawing on their NDPH research, worldwide between 1985 and 1993. been overloaded to have little or no effect on mortality or Professor Peto and Professor To recruit as many participants participate.” other important clinical outcomes. In Hongchao Pan worked closely with as possible, the studies involved June, the RECOVERY trial announced the WHO principal investigator on integrating the trials with clinical Dr Tedros Adhanom that dexamethasone, a low-cost governance and study conduct, and practice, simplifying the recruitment Ghebreyesus, and widely available corticosteroid made a major contribution to analysis, and data entry processes, and using WHO Director-General regimen, saves the lives of those with interpretation and presentation of government records for follow-up. severe COVID-19. SOLIDARITY trial datasets. Diagnostic testing Surveillance Infection control Longer-term effects Wider impacts Public debate on clinical outcomes to COVID-19 Co-development Panel have worked The COVID-19 in Pregnancy study Enabling the researchers, the team, led by Professor closely with the NHS DigiTrials team is investigating the incidence of provision Martin Landray, quickly refocused to ensure that patient and public COVID-19 infection, and answering efforts on linking trial cohorts to NHS feedback has been included in the these critical questions: of outcome data data sources, so that researchers design of
Load more

Recommended publications
  • Biovu Vanderbilt
    International Cohorts Summit JB Duke Hotel Durham, North Carolina, USA March 26 – 27, 2018 Summit Objectives The International Cohorts Summit was conceived by the Heads of International Research Organizations (HIROs) group co-chaired by Francis Collins at the National Institutes of Health (NIH) and Jeremy Farrar of the Wellcome Trust. Dr. Collins and Dr. Farrar reached out to the Global Genomic Medicine Collaborative (G2MC, www.g2mc.org), to organize a first forum with the goal of enabling leaders of large-scale longitudinal cohorts worldwide to share best practices, discuss data sharing, explore standards, discuss common challenges, and explore the potential for a larg(er) collaborative sequencing strategy. The primary objectives of this meeting will include: ● Improving prospects for interoperability and compatibility of instruments, data formats, phenotypic and clinical measures, etc ● Promoting data sharing and open access policies ● Broadening international cooperation through existing tools and resources ● Exploring the feasibility of a "digital" platform, or web-based, evolving registry of large-scale cohorts, in searchable format ● Examining the potential for a collaborative sequencing (and other -omics?) strategy ● Considering strategies for translating findings for health impact ● Advancing a collective vision: where do we want to be in ten years? We thank you for joining us at this pivotal event, and for contributing to our shared goal of enhanced international collaboration across research projects. Programme Committee Geoff
    [Show full text]
  • Trustees' Report and Financial Statements 2015-2016
    TRUSTEES’ REPORT AND FINANCIAL STATEMENTS 1 Trustees’ report and financial statements For the year ended 31 March 2016 2 TRUSTEES’ REPORT AND FINANCIAL STATEMENTS Trustees Executive Director The Trustees of the Society are the Dr Julie Maxton members of its Council, who are elected Statutory Auditor by and from the Fellowship. Council is Deloitte LLP chaired by the President of the Society. Abbots House During 2015/16, the members of Council Abbey Street were as follows: Reading President RG1 3BD Sir Paul Nurse* Bankers Sir Venki Ramakrishnan** The Royal Bank of Scotland Treasurer 1 Princes Street Professor Anthony Cheetham London EC2R 8BP Physical Secretary Professor Alexander Halliday Investment Managers Rathbone Brothers PLC Foreign Secretary 1 Curzon Street Sir Martyn Poliakoff CBE London Biological Secretary W1J 5FB Sir John Skehel Internal Auditors Members of Council PricewaterhouseCoopers LLP Sir John Beddington CMG* Cornwall Court Professor Andrea Brand 19 Cornwall Street Sir Keith Burnett** Birmingham Professor Michael Cates B3 2DT Dame Athene Donald DBE* Professor George Efstathiou** Professor Brian Foster** Professor Carlos Frenk* Registered Charity Number 207043 Professor Uta Frith DBE Registered address Professor Joanna Haigh 6 – 9 Carlton House Terrace Dame Wendy Hall DBE London SW1Y 5AG Dr Hermann Hauser Dame Frances Kirwan DBE* royalsociety.org Professor Ottoline Leyser CBE* Professor Angela McLean Dame Georgina Mace CBE Professor Roger Owen* Dame Nancy Rothwell DBE Professor Stephen Sparks CBE Professor Ian Stewart Dame Janet Thornton DBE Professor Cheryll Tickle** Dr Richard Treisman** Professor Simon White** * Until 30 November 2015 ** From 30 November 2015 Cover image Tadpoles overhead by Bert Willaert, Belgium. TRUSTEES’ REPORT AND FINANCIAL STATEMENTS 3 Contents President’s foreword ...............................................
    [Show full text]
  • Oration by the Vice-Chancellor
    WEDNESDay 14 octobEr 2015 • SUPPLEMENt (1) to No 5108 • VoL 146 Gazette Supplement Oration by the Vice-Chancellor colleagues and friends of the University, but my purpose today is larger than personal which, it was also interesting to note in a thank you very much indeed for joining memories, much as I will treasure them. If recent Times Higher survey, was ranked as me at the start of another academic year: some of the following sounds like a State one of the leanest in the UK. an academic year which will, of course, see of the Union address, it is not because my the figures I mentioned are impressive, but me depart from a role that I have enjoyed new, american, title of President has gone the reality they reflect is more impressive thoroughly for some six years. to my head. I believe there is some analogy still. People invest in oxford research between the collegiate University and the Dr Johnson said: ‘When a man knows he is because it guarantees world-class quality. federal USa. Like them, we aspire towards to be hanged in a fortnight, it concentrates the question of overall performance in a more perfect Union, even if perfection his mind wonderfully.’ My own situation, in the UK’s research Excellence Framework itself will always remain out of reach. I also leaving for New york University, is not quite assessment is often a contentious one. there believe I can stand before you today and so dramatic. Nevertheless, the prospect of are at least 18 different ways to calculate state that, at oxford, the State of our Union is my impending departure from oxford has it.
    [Show full text]
  • Sign-On Letter to Ask World Health Organization Executive Board Members to Support the Resolution on A
    Sign-on Letter to ask World Health Organization Executive Board members to support the resolution on a "Global Framework on Essential Health Research and Development" proposed by the Republic of Kenya at the January 2006 meeting. January 25th, 2006 Open Letter to the WHO Executive Board Dear Members of the WHO Executive Board: As scientists, many of whom work in fields connected with biomedicine, we are writing to express our support for the resolution submitted by the Republic of Kenya at the 117th meeting of the WHO Executive Board on January 23rd 2006. Although we have very varied scientific backgrounds, from basic research to specific clinical research, we are all deeply concerned with deficiencies in the way that biomedical research science is supported and translated into treatments that improve health outcomes around the world. In the research setting we see many possibilities to develop drugs to treat neglected diseases, but a lack of sustainable support for the R&D process. In the clinical setting we see the problem of affordable drugs to a greater or lesser extent in health care systems in all countries. At a time of huge progress in basic research science and more money being spent on biomedical R&D than ever, we are deeply concerned about the ability of existing mechanisms to translate this into a global improvement in public health. We have all felt the impact and promise of the free availability of genome sequence data, notably from the human genome project. At the same time we see research activities increasingly complicated by legal restrictions, such as intellectual property rights, which can interfere with free data exchange and can limit biomedical research progress.
    [Show full text]
  • BLUEPRINT July 2015 RESEARCH ROUND-UP
    blueprint Staff magazine for the University of Oxford | July 2015 Pre-sessional support | The ruskin revealed | Staff sports special News in brief u Oxford’s work on precision cancer medicine u Oxford’s self-service bike share scheme, has received a significant boost after Cancer part-funded by the University, has recently Research UK announced that it would give been expanded to include docking stations ‘Major Centre’ status to the Cancer Research at the University Science Area (Hinshelwood UK Oxford Centre and an extra £5m over Road), Littlemore Mental Health Centre, two years. The Oxford Centre, which is a Warneford Hospital and Chancellor Court. partnership between the University, Oxford The OXONBIKE scheme now has 11 stations University Hospitals NHS Trust and Cancer and 66 bikes linking the hospitals, science AshmoleanMuseum Research UK, acts as a major research hub for area and Headington shops. Bikes can be a network of similar centres, drawing together picked up and dropped off at any docking expertise from different fields, encouraging station in the network. Registration collaborative research and bridging the gap is just £1 and journeys under 30 minutes between innovative laboratory work and are free. For details and to register, visit benefits for patients. www.oxonbikes.co.uk. Museumof Natural History u The Ashmolean has raised the money u Are you interested in taking a course at needed to acquire a major painting by J M the Department for Continuing Education? Aldebaran RoboticsAlcock Aldebaran / Ed W Turner. The High Street, Oxford (1810), Courses range from single-day events to full which has been on loan to the museum from degree programmes, and over 60 subject a private collection since 1997, is Turner’s areas are on offer in the humanities, social only full-size townscape in oils.
    [Show full text]
  • Evaluating Evidence in Health’
    Perspectives on ‘Evaluating evidence in health’ A workshop report from a joint meeting held by the Academy of Medical Sciences and the Wellcome Trust on 21 October 2015 Disclaimer This report does not represent a formal Academy of Medical Sciences or Wellcome Trust position on the evaluation of evidence in health. Rather this document reflects the wide-ranging discussions that took place at the workshop. It does not necessarily represent the views of all participants, the Academy of Medical Sciences or the Wellcome Trust. The report of this meeting will feed into the Academy’s workstream on ‘Enhancing the use of scientific evidence to judge the potential harms and benefits of medicines?’, including its sub-project on the ‘Sources of evidence for assessing the safety, efficacy and effectiveness of medicines’.1,2 It will also inform the Wellcome Trust’s thinking on accelerating uptake of research into policy and practice.3 For further information, please contact Dr Claire Cope, Policy Manager at the Academy of Medical Sciences: [email protected], (0)20 3141 3218. All web references were accessed in November/December 2015. This work is © Academy of Medical Sciences and is licensed under Creative Commons Attribution 4.0 International. 1 Led by Professor Sir John Tooke FMedSci, the workstream also includes workshops on conflicts of interest and communicating evidence. For further information, please see: http://www.acmedsci.ac.uk/policy/policy- projects/how-can-we-all-best-use-evidence/ 2 http://www.acmedsci.ac.uk/policy/policy-projects/methods-of-evaluating-evidence/ 3 http://strategy.wellcome.ac.uk Perspectives on ‘Evaluating evidence in health’ A workshop report from a joint meeting held by the Academy of Medical Sciences and the Wellcome Trust on 21 October 2015 Contents Executive summary ...................................................................................................
    [Show full text]